Results 61 to 70 of about 12,722 (192)

What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? [PDF]

, 2017
AIMS: The PARADIGM-HF trial showed that sacubitril-valsartan, an ARB-neprilysin inhibitor, is more effective than enalapril for some patients with heart failure (HF).
Clark, Andrew L., Cleland, John G. F., Dierckx, Riet, Kazmi, Syed, MacNamara, Alexandra, Pellicori, Pierpaolo, Shah, Parin, Urbinati, Alessia, Zhang, Jufen   +8 more
core   +3 more sources

Machine learning‐based prediction of elevated N terminal pro brain natriuretic peptide among US general population

ESC Heart Failure, Volume 12, Issue 2, Page 859-868, April 2025.
Abstract Aims Natriuretic peptide‐based pre‐heart failure screening has been proposed in recent guidelines. However, an effective strategy to identify screening targets from the general population, more than half of which are at risk for heart failure or pre‐heart failure, has not been well established.
Yuichiro Mori, Shingo Fukuma, Kyohei Yamaji, Atsushi Mizuno, Naoki Kondo, Kosuke Inoue   +5 more
wiley   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Sacubitril/valsartan: um importante avanço no puzzle terapêutico da insuficiência cardíaca

Revista Portuguesa de Cardiologia, 2017
Resumo: O sacubitril/valsartan (LCZ696) é um complexo supramolecular de sal de sódio do pró‐fármaco sacubitril, inibidor da neprilisina, e do valsartan, um antagonista dos recetores da angiotensina (ARB), administrado por via oral, recentemente aprovado ...
Pedro Marques da Silva, Carlos Aguiar
doaj   +1 more source

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice

Frontiers in Endocrinology, 2022
Treatment of heart failure with the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan improved glycemic control in individuals with type 2 diabetes. The relative contribution of neprilysin inhibition versus angiotensin II receptor antagonism
Nathalie Esser, Nathalie Esser, Nathalie Esser, Christine Schmidt, Breanne M. Barrow, Laura Cronic, Daryl J. Hackney, Stephen M. Mongovin, Meghan F. Hogan, Meghan F. Hogan, Andrew T. Templin, Andrew T. Templin, Joseph J. Castillo, Joseph J. Castillo, Rebecca L. Hull, Rebecca L. Hull, Sakeneh Zraika, Sakeneh Zraika   +17 more
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)

Scientific Reports
Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, is widely used to treat heart failure. Despite its efficacy, sacubitril/valsartan inevitably causes adverse events such as hypotension, renal dysfunction, hyperkalemia, and
Ning Wang, Haijun Wang, Ying Chen, Yanfeng Wang   +3 more
doaj   +1 more source

Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials

Frontiers in Cardiovascular Medicine, 2022
AimsThe efficacy and safety of sacubitril/valsartan for patients with heart failure with preserved ejection fraction (HFpEF) are controversial. Hence, the primary objective of the study was to evaluate the efficacy and safety of sacubitril/valsartan ...
Wanqian Yu, Hongzhou Zhang, Wen Shen, Fan Luo, Shuai Yang, Lujin Gan, Yuanbin Zhao, Pingping Yang, Qinghua Wu   +8 more
doaj   +1 more source

The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective. [PDF]

, 2016
AIMS: Heart failure (HF) treatment guided by physicians with access to real-time pressure measurement from a wireless implantable pulmonary artery pressure (PAP) sensor (CardioMEMS), has previously been shown to reduce HF-related hospital admissions in ...
Abraham, Abraham, Adamson, Adamson, Berg, Boyne, Braunschweig, Briggs, Chaudhry, Cleland, Cleland, Cotter, Curtis, Drummond, Gheorghiade, Griffiths, Inglis, Jeon, Jhund, Kato, Klersy, Koehler, Martinson, Matza, Mitchell, Mosterd, Ong, Pandor, Ponikowski, Sandhu, Schiff, Thokala, Townsend   +32 more
core   +2 more sources